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Abstract
Background:  The inhibitor of DNA-binding (ID) has been involved in cell cycle regulation,
apoptosis and angiogenesis. This prompted us to study ID functions in tumor advancement of
ovarian cancers.
Methods: Sixty patients underwent surgery for ovarian cancers. In ovarian cancers, the levels of
ID-1, ID-2 and ID-3 mRNAs were determined by real-time reverse transcription-polymerase chain
reaction. The histoscore with the localization of ID-1 was determined by immunohistochemistry.
Patient prognosis was analyzed with a 36-month survival rate. Microvessel counts were determined
by immunohistochemistry for CD34 and factor VIII-related antigen.
Results: ID-1 histoscores and mRNA levels both significantly (p < 0.001) increased in ovarian
cancers according to clinical stage, regardless of histopathological type. Furthermore, 30 patients
with high ID-1 expression had a lower survival rate (53%) compared to patients with low ID-1
expression (80%). ID-1 histoscores and mRNA levels significantly (p < 0.0001) correlated with
microvessel counts in ovarian cancers.
Conclusion: ID-1 increased in ovarian cancer cells during tumor progression. Moreover, ID-1
expression levels correlated with microvessel counts. Therefore, ID-1 might work on tumor
advancement via angiogenesis and is considered to be a candidate for a prognostic indicator in
ovarian cancers.
Background
Inhibitor of DNA binding (ID) proteins are members of a
family of basic helix-loop-helix (bHLH) transcription fac-
tors lacking the DNA-binding domain [1]. ID acts as dom-
inant-negative regulators of bHLH proteins by forming
transcriptionally inactive Id-bHLH protein complexes
[2,3]. ID has been implicated in different steps in tumori-
genesis, differentiation and metastasis [4-9].
ID-1 induces cell proliferation, increases DNA synthesis,
and immortalizes mammalian cells in corporation with
some oncogenes [10,11]. Overexpression of ID-1 inhibits
expression of p16 [12,13], p21 [14] and p27 [15], which
leads to increased activity of cyclin dependent kinase 2
(CDK2) and increased phosphorylation of retinoblast-
oma protein. Therefore, the increased liberation of ID-2
from retinoblastoma protein and more free-ID-2 is avail-
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able for the inhibition of E proteins to facilitate prolifera-
tion [16]. ID-1 interacts with various cell cycle regulators
[12,17] and causes cells to pass a mitogen-restricted point
in late G1 phase [18]. Therefore, ID-1 is responsible for
some changes in gene expression that lead to growth and
invasion of tumor cells [19]. Moreover, ID-1 plays various
roles such as markers for progression, metastasis and
prognosis in prostate [20,21], breast [22,23], gastric
[24,25], esophageal [26] and uterine cervical cancers [27].
In a previous study, expression of ID-1 was shown as an
independent prognostic factor in ovarian cancer with
long-time follow-up. Overexpression of ID-1 is associated
with more aggressive behavior of tumor cells in ovarian
cancer [28]. However, no study has investigated the
molecular function of ID-induced tumor progression in
ovarian cancer. This prompted us to study the expression
manner of ID proteins in ovarian cancers against clinical
backgrounds with angiogenic potential in the tumors.
Methods
Patients and tissues
Prior informed consent for the following studies was
obtained from all patients and approval was given by the
Research Committee for Human Subjects, Gifu University
School of Medicine. Sixty patients ranging from 34 to 83
years of age with ovarian cancers [stage I, 18 cases; stage II,
13 cases; and stage III, 15 cases; stage IV, 14 cases; 23 cases
of serous papillary cystadenocarcinoma (SPCY), 8 cases of
serous cystadenocarcinoma (SCY), 10 cases of mucinous
cystadenocarcinoma (MCY), 8 cases of clear cell adenocar-
cinoma (C) and 11 cases of endometrioid adenocarci-
noma (E)] underwent surgery at the Department of
Obstetrics and Gynecology, Gifu University School of
Medicine, between December 1997 and January 2004.
Patient prognosis was analyzed in relation to a 36-month
survival rate. None of the patients had received any pre-
operative therapy before the ovarian cancer tissue was
taken in surgery. A part of each tissue of ovarian cancers
was snap-frozen in liquid nitrogen and stored at -80°C to
determine ID-1, ID-2 and ID-3 mRNA levels and those for
immunohistochemistry were fixed with 10% formalin
and embedded in paraffin wax. The clinical stage of ovar-
ian cancers was determined by International Federation of
Obstetrics and Gynecology (FIGO) classification [29].
Immunohistochemistry
Sections (4 μm) of formalin-fixed paraffin-embedded tis-
sue samples from ovarian cancers were cut with a micro-
tome and dried overnight at 37°C on a silanized-slide
(Dako, Carpinteria, CA, USA). The protocol of universal
Dako-Labelled Streptavidin-Biotin kit (Dako, Carpinteria,
CA, USA) was followed for each sample. Samples were
deparaffinized in xylene at room temperature for 30 min,
rehydrated with graded ethanol and washed in phos-
phate-buffered saline (PBS). The samples were then
placed in 10 mM citrate buffer (pH 6.0) and boiled in a
microwave for 10 min for epitope retrieval. Endogenous
peroxidase activity was quenched by incubating tissue sec-
tions in 3% H2O2 for 10 min. The primary antibodies, rab-
bit antihuman ID-1 (SC-734, Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA), mouse CD34 (Dako, Glos-
trup, Denmark) and rabbit anti-factor VIII-related antigen
(Zymed, San Francisco, CA, USA) were used overnight at
4°C at dilutions of 1:50, 1:40 and 1:2, respectively. The
slides were washed and biotinylated secondary antibody
(Dako, Carpinteria, CA, USA) was applied for 30 min after
rinsing in PBS, after which streptavidin-conjugated horse-
radish peroxidase (Dako, Carpinteria, CA, USA) was
added for 30 min. Slides were then washed and treated
with the chromogen 3,3'-diaminobenzidine (Dako,
Carpinteria, CA, USA) for 5 min, then rinsed in PBS, and
counterstained with Mayer's haematoxylin, dehydrated in
graded ethanols, cleared in xylene and cover-slipped with
a mounting medium, Entellan New (Merck, Darmstadt,
Germany). For confirmation of the specificity for ID-1
antigen, we also used another ID-1 (SC-488) rabbit poly-
clonal antibody (Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA) and we have observed the exact identified
intensity and localization of staining for ID-1 expression
in tumor cells as ID-1 (SC-734) antibody. For the negative
controls, the primary antibodies of ID-1, CD34 and factor
VIII-related antigen were omitted and the corresponding
preimmune animal serums (rabbit, mouse and rabbit,
respectively) (Dako, Carpinteria, CA, USA) were used
instead.
Assessment of histochemical score (histoscore)
All sections of immunohistochemical staining for ID-1
were evaluated in a semiquantitative fashion according to
the method described by McCarty et al. [30], which con-
siders both the intensity and the percentage of cells
stained in each of five intensity categories. Intensities were
classified as 0 (no staining), 1 (weak staining), 2 (distinct
staining), 3 (strong staining) and 4 (very strong staining).
For each stained section, a value-designated histoscore
was obtained by application of the following algorithm:
histoscore = Σ(i+1) × Pi, where i and Pi represent intensity
and percentage of cells that stain at each intensity, respec-
tively, and corresponding histoscores were calculated sep-
arately. Results were assigned to four groups according to
their overall scores: weak, <160; distinct, 161<, >220;
strong, 221<, >280; very strong, 280<.
Assessment of microvessel density (MVD)
The MVD was assessed with microvessel counts (MVCs) in
sequential tissue sections stained with mouse CD34 and
rabbit factor VIII-related antigen antibodies. Blood vessels
with a clearly defined lumen or a well defined linear vessel
shape, but not single endothelial cells, were taken intoBMC Cancer 2009, 9:430 http://www.biomedcentral.com/1471-2407/9/430
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account for microvessel counting [31]. Fives areas of high-
est vascular density were chosen and microvessel counting
was performed at ×200 magnification by two investiga-
tors. The MVCs were determined as the mean of the vessel
counts obtained from these fields [32].
Preparation of standard template for real-time reverse 
transcription-polymerase chain reaction (RT-PCR)
Internal standard template for real-time PCR was pro-
duced by PCR amplification using the primers of ID-1
gene, 418-782 in the cDNA (ID-1-TS: 5'-TTGGAGCT-
GAACTCGGAA-3' and ID-1-TAS: 5'-TCTCTGGTGACTAG-
TAGGT-3'); ID-2 gene, 907-1253 in the cDNA (ID-2-TS:
5'-CTAAGCAGACTTTGCCTTT-3' and ID-2-TAS: 5'-
CTGAAATAAAGCAGGCAATC-3'); ID-3 gene, 686-1009
in the cDNA (ID-3-TS: 5'-GAACTTGTCATCTCCAACGA-3'
and ID-3-TAS: 5'-CACGCTCTGAAAAGACCT-3'). The
DNA template was purified using a GeneClean II kit
(Qbiogene, Irvine, CA, USA). The copy numbers of the
standard template were determined to quantitate ID-1,
ID-2 and ID-3 mRNA level in samples for real-time RT-
PCR.
Real-time RT-PCR to amplify ID-1, ID-2 and ID-3 mRNAs
Total RNA was extracted with the acid guanidinium thio-
cyanate-phenol-chloroform method [33]. The total RNA
(3  μg) was reverse transcribed using Moloney murine
leukemia virus reverse transcriptase (MMLV-RT, 200 U/μl,
Invitrogen, Carlsbad, CA, USA) and the following rea-
gents: 250 mM Tris-HCl, pH 8.3, 375 mM KCl, 15 mM
MgCl2, 0.1 M dithiothreitol, 10 mM deoxynucleotide
[deoxyadenosine, deoxythymidine, deoxyguanosine and
deoxycystidine] tri-phosphates (dNTPs) mixture and ran-
dom hexamers (Invitrogen) at 37°C for 1 h. The reaction
mixture was heated for 5 min at 94°C to inactivate
MMLV-RTase.
Real-time PCR reaction was performed with a Takara
Premix Ex Taq (Perfect Real Time) R-PCR kit (Takara,
Otsu, Japan), using a smart cycler system (Cepheid, Sun-
nyvale, CA, USA). The reaction solution (25 μl) contained
Takara Premix Ex Taq (2×), SYBR Green I (1:1000 dilu-
tion; CambrexBio Science, Rockland Inc., Rockland, ME,
USA) and 20 μM of the primers of ID-1 gene, 545-675 in
the cDNA (ID-1-S: 5'-ACGATCGCATCTTGTGTC-3' and
ID-1-AS: 5'-CTTGTTCTCCCTCAGATCC-3'); ID-2 gene,
907-1026 in the cDNA (ID-2-S: 5'-CTAAGCAGACTTT-
GCCTTT-3' and ID-2-AS: 5'-CATTCAGTAGGCTTGTGTC-
3'); ID-3 gene, 709-873 in the cDNA (ID-3-S: 5'-AAG-
GAGCTTTTGCCACTGA-3' and ID-3-AS:5'-CCAGGAAG-
GGATTTGGTGAA-3') with the transcribed total RNA from
the tissue and a serially diluted standard template. The
real-time PCR reactions were initially denatured by heat-
ing at 95°C for 30 s, followed by 40 cycles consisting of
denaturation at 94°C for 10 s, annealing at 55°C for 5 s
and extension at 72°C for 20 s. A strong linear relation-
ship between the threshold cycle and the log concentra-
tion of the starting DNA copy number was always shown
(correlation coefficient > 0.99). Quantitative analysis was
performed to determine the copy number of each sample.
Statistical analysis
ID-1, ID-2 and ID-3 mRNA levels were determined from
three parts taken from each tumor, and each sample was
analyzed in triplicate. Statistical analysis was performed
using MedCalc Software version 9.2.0.1. ID-1 histoscores
and mRNA levels were compared using the Mann-Whit-
ney test and the Kruskal-Wallis test as appropriate. The 36-
month survival rate was calculated according to the Kap-
lan-Meier method. The log-rank test and the Cox propor-
tional hazards model were used for univariate and
multivariate analyses of overall survival, respectively. The
correlations between ID-1 histoscores and mRNA levels
with MVCs were performed with Spearman's coefficient of
correlation just for descriptive analysis. Differences were
considered significant when P was less than 0.05.
Results
ID-1 mRNA levels significantly increased with increasing
clinical stages (p < 0.001) of ovarian cancers, regardless of
histopathological type (Figure 1). However, there was no
significant difference in ID-2 or ID-3 mRNA levels accord-
ing to clinical stage or histopathological type in ovarian
cancers, as shown in Figure 1. These results prompted us
to concentrate our investigation on ID-1 in ovarian can-
cers.
Although ID-1 expression in stroma cells was negative,
ID-1 staining was diffusely located in the cancer cells (Fig-
ure 2, a representative case of clear cell carcinoma of
ovary). Because ID-1 is not a transcription factor per se, it
lacks the nuclear localization signal found on many basic
HLH proteins but gives a cytoplasmic signal instead
[34,35]. ID-1 diffuse cytoplasmic staining was seen from
moderate to strong intensity in most cases whereas
nuclear staining was observed only occasionally (Figure
2).
ID-1 histoscore in cancer cells significantly (p < 0.001)
correlated with the corresponding mRNA levels in each
tissue, as shown in Figure 3. Although there was no signif-
icant difference in ID-1 histoscores in cancer cells accord-
ing to histopathological type, ID-1 histoscores
significantly (p < 0.001) increased with increased clinical
stages of ovarian cancers (Figure 4), as did ID-1 mRNA.
Furthermore, the 60 patients who underwent surgery were
divided into two equal groups based on ID-1 histoscores
and mRNA levels, with the midpoint being a histoscore of
160 and mRNA of 6.2 × 106 copies/μg total RNA, respec-BMC Cancer 2009, 9:430 http://www.biomedcentral.com/1471-2407/9/430
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tively. The two groups, determined independently by the
ID-1 histoscores and mRNA levels, consisted of exactly the
same patients. The prognosis of the 30 patients with high
ID-1 (> 160 histoscore and > 6.2 × 106 copies/μg total
RNA) in ovarian cancers was poor (53%), whereas the 36-
month survival rate of the other 30 patients with low ID-
1 (< 160 histoscore and < 6.2 × 106 copies/μg total RNA)
was higher (80%), as shown in Figure 5.
ID-1 expression was negative in endothelial cells,
although CD34 and Factor VIII-related antigen expres-
sions were strong. ID-1 histoscores significantly correlated
with MVC-CD34 (MVCs determined by immunohisto-
chemistry for CD34; r = 0.6296, p < 0.0001) and MVC-F-
VIII (MVCs determined by immunohistochemistry for
ID-1, ID-2 and ID-3 mRNA levels in ovarian cancers classified  according to clinical stage and histopathological type Figure 1
ID-1, ID-2 and ID-3 mRNA levels in ovarian cancers 
classified according to clinical stage and histopatho-
logical type. Clinical staging of ovarian cancers was done 
according to FIGO. Each level is the mean ± SD of nine 
determinations. C, clear cell carcinoma; E, endometrioid ade-
nocarcinoma; MCY, mucinous cystadenocarcinoma; SCY, 
serous cystadenocarcinoma, SPCY, serous papillary cystade-
nocarcinoma. Alive and deceased cases are numbered in 
open circles and closed circles, respectively. * p < 0.001.
Immunohistochemical staining for ID-1 with negative control  in ovarian cancers Figure 2
Immunohistochemical staining for ID-1 with negative 
control in ovarian cancers. A representing case of clear 
cell carcinoma of the ovary. Rabbit anti-human ID-1 (SC-734, 
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was 
used at a dilution of 1:50 as the primary antibody. (original 
magnification ×400).
Correlation between ID-1 histoscores in cancer cells and  mRNA (106 DNA copies/μg total RNA) levels in ovarian can- cers Figure 3
Correlation between ID-1 histoscores in cancer cells 
and mRNA (106 DNA copies/μg total RNA) levels in 
ovarian cancers. ID-1 histoscores and mRNA levels were 
determined by immunohistochemistry and real-time RT-
PCR, respectively. Each level is the mean ± SD of nine deter-
minations.
ID-1 histoscores in ovarian cancers classified according to  clinical stage and histopathological type Figure 4
ID-1 histoscores in ovarian cancers classified accord-
ing to clinical stage and histopathological type. Clinical 
staging of ovarian cancers was done according to FIGO. Each 
level is the mean ± SD of nine determinations. C, clear cell 
carcinoma; E, endometrioid adenocarcinoma; MCY, muci-
nous cystadenocarcinoma; SCY, serous cystadenocarci-
noma, SPCY, serous papillary cystadenocarcinoma. Alive and 
deceased cases are numbered in open circles and closed cir-
cles, respectively. * p < 0.001.BMC Cancer 2009, 9:430 http://www.biomedcentral.com/1471-2407/9/430
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factor VIII-related antigen; r = 0.5698, p < 0.0001), and
ID-1 mRNA levels also correlated with MVC-CD34 (r =
0.7686, p < 0.0001) and MVC-F-VIII (r = 0.5792, p <
0.0001), as shown in Figure 6.
Discussion and conclusion
In the present study, ID-1 expression increased with
tumor advancement of ovarian cancers and patients with
high ID-1 expression had a lower survival rate compared
to patients with low ID-1 expression. Previously, no corre-
lation between expression of ID proteins and angiogen-
esis, assessed by MVD was observed in ovarian cancers
[28].
Ectopic expression of ID-1 in a prostate cancer cell line
that express low levels of both ID-1 and VEGF protein
resulted increase in VEGF secretion by the cells, which is
associated with increased VEGF gene transcription, after
ID-1 gene transfection [36]. ID-1 promotes tumor angio-
genesis through VEGF gene transcription and protein
expression. In addition, VEGF is a downstream target of
the ID-1 protein [36]. ID-1 promotes tumor angiogenesis
through induction of the VEGF gene transcription and
protein expression [37-39], leading to proliferation and
endothelial tube formation of the vascular endothelial
cells. ID-1 induces activity of HIF-1α in human endothe-
lial and breast cancer cells [40,41]. Furthermore, ID-1
enhanced nuclear translocation and the transcriptional
activity of HIF-1α [42]. In a previous study, increased HIF-
1α levels were observed with tumor advancement and
poor patient prognosis in uterine cervical cancers [43].
When tumor xonografts were implanted into ID-1/ID-3
mice, decreased tumor growth as well as loss of metastasis
were observed, which were associated with impaired neo-
vascularization of tumor [19]. In ID-1/- mice, up-regula-
tion of a potent angiogenic inhibitor thrombospondin-1
in null embryonic fibroblasts was observed [44]. This
showed ID-1 alone was sufficient to impair tumor angio-
genesis. In the present study, ID-1 expression correlated
with microvessel counts indicating that ID-1 overexpres-
sion contributed to tumor angiogenesis in ovarian cancer.
Therefore, ID-1 is a candidate for angiogenic mediator as
the clinical relevance of angiogenesis assessed by MVC.
In conclusion, this study demonstrates the functional role
of ID-1 overexpression in tumor advancement via angio-
genesis and ID-1 can be a useful prognostic indicator in
ovarian cancers. In addition, ID-1 protein might be an
important new target molecule for anti-angiogenic drug
design in cancer treatment.
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Survival rate after surgery for ovarian cancers Figure 5
Survival rate after surgery for ovarian cancers. Patient 
prognosis was analyzed with a 36-month survival rate. High 
ID-1, cases with high histoscores and mRNA levels (> 160 
histoscore and > 6.2 × 106copies/μg total RNA, respec-
tively). Low ID-1, cases with low histoscores and mRNA lev-
els (< 160 histoscore and < 6.2 × 106 copies/μg total RNA, 
respectively).
Correlation of ID-1 histoscores in cancer cells and mRNA  levels in ovarian cancers with microvessel counts (MVCs) Figure 6
Correlation of ID-1 histoscores in cancer cells and 
mRNA levels in ovarian cancers with microvessel 
counts (MVCs). White circles, (MVC-CD34) by immuno-
histochemical staining for CD34; black circles, (MVC-FV-III) 
by immunohistochemical staining for factor VIII-related anti-
gen. Each level is the mean ± SD of nine determinations.BMC Cancer 2009, 9:430 http://www.biomedcentral.com/1471-2407/9/430
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